Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MRK

Merck & Co Inc

Nov 03 • 04:00PM ET

82.49

-3.49 -4.06 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE AZN NVS BMY JNJ AMGN ABBV GSK LLY SNY

| Held by: VTI VOO SCHD IVV SPY VTV XLV VIG VYM DGRO

Scroll to Statements

Index	DJIA, S&P 500	P/E	10.91	EPS (ttm)	7.56	Insider Own	0.10%	Shs Outstand	2.50B	Perf Week	-6.26%
Market Cap	206.04B	Forward P/E	8.79	EPS next Y	9.38	Insider Trans	0.00%	Shs Float	2.50B	Perf Month	-7.51%
Enterprise Value	232.85B	PEG	1.06	EPS next Q	2.10	Inst Own	80.39%	Short Float	1.07%	Perf Quarter	2.10%
Income	19.03B	P/S	3.22	EPS this Y	16.99%	Inst Trans	-0.69%	Short Ratio	2.27	Perf Half Y	-0.42%
Sales	63.99B	P/B	4.21	EPS next Y	4.82%	ROA	14.26%	Short Interest	26.70M	Perf YTD	-17.08%
Book/sh	19.57	P/C	23.78	EPS next 5Y	10.27%	ROE	35.44%	52W High	105.07 -21.49%	Perf Year	-21.31%
Cash/sh	3.47	P/FCF	14.00	EPS past 3/5Y	9.42% 12.04%	ROIC	22.94%	52W Low	73.31 12.52%	Perf 3Y	-17.29%
Dividend Est.	3.23 (3.92%)	EV/EBITDA	8.70	Sales past 3/5Y	9.36% 6.55%	Gross Margin	82.76%	Volatility	3.00% 2.09%	Perf 5Y	10.93%
Dividend TTM	3.24 (3.93%)	EV/Sales	3.64	EPS Y/Y TTM	20.01%	Oper. Margin	39.88%	ATR (14)	2.01	Perf 10Y	63.51%
Dividend Ex-Date	Sep 15, 2025	Quick Ratio	1.17	Sales Y/Y TTM	1.74%	Profit Margin	29.75%	RSI (14)	38.16	Recom	2.03
Dividend Gr. 3/5Y	5.73% 6.66%	Current Ratio	1.42	EPS Q/Q	86.41%	SMA20	-4.27%	Beta	0.35	Target Price	101.32
Payout	46.32%	Debt/Eq	0.72	Sales Q/Q	3.36%	SMA50	-2.42%	Rel Volume	1.17	Prev Close	85.98
Employees	75000	LT Debt/Eq	0.69	Earnings	Oct 30 BMO	SMA200	-2.28%	Avg Volume	11.79M	Price	82.49
IPO	Jun 15, 1946	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.21% 1.75%	Trades		Volume	13,849,342	Change	-4.06%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-13-25	Resumed	Citigroup	Neutral	$95
Sep-17-25	Downgrade	Berenberg	Buy → Hold	$90
May-14-25	Downgrade	Citigroup	Buy → Neutral	$84
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$85
Feb-18-25	Downgrade	Deutsche Bank	Buy → Hold	$128 → $105
Feb-10-25	Downgrade	TD Cowen	Buy → Hold	$121 → $100
Jan-08-25	Downgrade	Truist	Buy → Hold	$110
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130

Show Previous Ratings

Nov-03-25 04:37PM	Stock Market Today: Indexes End Mixed, But Palantir Pops; This Tech Stock Drops Amid AMD Lawsuit (Live Coverage) (Investor's Business Daily)
03:09PM	Stock Market Today: Nasdaq Up With Amazon Jump; This Tech Stock Drops Amid AMD Lawsuit (Live Coverage) (Investor's Business Daily)
01:38PM	Stock Market Today: Dow Down, But Amazon Leaps On OpenAI Move; This Stock Soars On Microsoft Deal (Live Coverage) (Investor's Business Daily)
12:25PM	Stock Market Today: Dow Dips But Amazon Surges On OpenAI Move; Kimberly-Clark Dives On $49 Billion Deal (Live Coverage) (Investor's Business Daily)
07:35AM	ESMO 2025: Sichuan-Kelun moves in breast cancer ADC space (Pharmaceutical Technology)
07:11AM	Loading…
07:11AM	Are Wall Street Analysts Predicting Merck & Co. Stock Will Climb or Sink? (Barchart)
06:45AM	Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S. (Business Wire)
06:35AM	ESMO 2025: Bayer and BI neck and neck in first line HER2+ NSCLC (Pharmaceutical Technology)
05:32AM	Merck & Co. Inc. (MRK) Reports Solid Q3 with Strong Drug Sales and Pipeline Progress (Insider Monkey)
Oct-31-25 06:29PM	Alternative Economic Data Point to Solid Growth (Barrons.com)
10:26AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
07:50AM	Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' quarter; Exxon, Chevron post strong earnings (Yahoo Finance)
Oct-30-25 04:41PM	Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' holiday quarter, Reddit and Coinbase rise (Yahoo Finance)
04:41PM	Earnings live: Amazon stock soars on AWS growth, Apple wavers, Reddit and Coinbase move higher (Yahoo Finance)
04:35PM	Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle (The Wall Street Journal)
04:31PM	Loading…
04:31PM	Merck & Co Inc (MRK) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges (GuruFocus.com)
01:22PM	Moderna stock soars after report of potential buyout talks (Investing.com)
12:41PM	MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down (Zacks)
10:41AM	Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Chipotle (The Wall Street Journal)
09:49AM	Merck Stock Falls. Sales of Key Products Missed Estimates. (Barrons.com)
09:46AM	Merck's (NYSE:MRK) Q3 Sales Top Estimates (StockStory)
09:30AM	Merck (MRK) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
09:25AM	Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook (Yahoo Finance Video)
08:41AM	Stock Market Today: Dow Falls On Trump-Xi Talks; Meta Plunges On Earnings (Live Coverage) (Investor's Business Daily)
08:19AM	Earnings live: Meta stock tumbles, Microsoft slides, and Alphabet jumps as Big Tech earnings pour in (Yahoo Finance)
07:45AM	Merck (MRK) Q3 Earnings and Revenues Beat Estimates (Zacks)
07:32AM	Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. (Barrons.com)
07:07AM	Merck narrows full-year sales guidance (Investing.com)
06:56AM	Merck Boosts FY25 Adj. EPS Outlook - Update (RTT News)
06:51AM	Merck Stock Falls After Earnings. Keytruda Sales Top $8 Billion for First Time. (Barrons.com)
06:48AM	Loading…
06:48AM	Merck: Q3 Earnings Snapshot (Associated Press Finance)
06:41AM	Merck Profit Rises on Strong Keytruda Demand (The Wall Street Journal)
06:30AM	Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results (Business Wire)
05:08AM	Apple and Amazon headline earnings slate (MarketWatch)
04:29AM	Stock Market Today: Dow, S&P 500 and Nasdaq hover near record highs after U.S.-China trade deal, while Meta stock dives but Alphabet pops on earnings; Apple and Amazon results on tap; Treasury yields up on December rate-cut pushback. (MarketWatch)
Oct-29-25 07:00PM	Apple & Amazon earnings, Fed, mortgage rates: What to Watch (Yahoo Finance Video)
04:33PM	Earnings live: Meta stock tumbles, Microsoft slides, and Alphabet rises as Big Tech earnings pour in (Yahoo Finance)
04:30PM	Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect. (Barrons.com)
08:58AM	Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings? (Zacks)
08:11AM	Earnings live: Boeing stock slips, Caterpillar surges, with results from Microsoft, Meta, and Alphabet on deck (Yahoo Finance)
08:11AM	Earnings live: Boeing stock slips as cash burn improves, Caterpillar and Verizon rise, Enphase tumbles (Yahoo Finance)
07:00AM	Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma (Business Wire)
06:45AM	European Commission Approves KEYTRUDA (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1) (Business Wire)
Oct-28-25 11:16PM	Merck (MRK) Reports Earnings Tomorrow: What To Expect (StockStory)
05:01PM	Earnings live: Wayfair stock soars following Q3 results, PayPal rises, Royal Caribbean slides (Yahoo Finance)
12:37PM	Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know (Zacks)
11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
10:13AM	As Dow Hits Record, High-Yield Dogs of the Dow Still a Bargain (24/7 Wall St.)
08:04AM	Earnings live: PayPal stock soars on OpenAI partnership, UPS surges, UnitedHealth pops (Yahoo Finance)
08:01AM	Merck kidney cancer drug succeeds in two large trials (BioPharma Dive)
06:45AM	Merck Announces KEYTRUDA (pembrolizumab) Plus WELIREG (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy (Business Wire)
06:30AM	Merck and Eisai Announce WELIREG (belzutifan) Plus LENVIMA (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (Business Wire)
06:00AM	Incyte trims pipeline; Zenas surges on MS drug results (BioPharma Dive)
Oct-27-25 05:47PM	Exxon and 9 More Dividend Stocks to Buy for a Rocky Market (Barrons.com)
04:51PM	Earnings live: Keurig Dr. Pepper stock pops, Waste Management and Whirlpool slip with Big Tech results on deck (Yahoo Finance)
02:00PM	3 Dividend-Paying Drug Stocks to Buy at a Discount (Motley Fool)
11:45AM	Are You Looking for a High-Growth Dividend Stock? (Zacks)
11:32AM	Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues (Zacks)
11:05AM	What's in Store for These 5 Pharma Bigwigs This Earnings Season? (Zacks)
10:45AM	3 Healthcare Stocks to Buy Hand Over Fist in October (Motley Fool)
09:19AM	JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio? (Zacks)
09:15AM	Merck (MRK) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
08:01AM	Earnings live: Keurig Dr. Pepper stock pops as investors await Big Tech earnings from Apple, Google, and more (Yahoo Finance)
06:45AM	U.S. FDA Approves Updated Indication for WINREVAIR (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study (Business Wire)
04:00AM	Mercks oncology prospects could portend a post-Keytruda future (Pharma Voice)
Oct-26-25 04:23PM	3 Healthcare Stocks That Are Screaming Deals Right Now (Motley Fool)
06:05AM	Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data (Insider Monkey)
Oct-24-25 07:00PM	Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch (Yahoo Finance Video)
10:05AM	Merck's Non-Oncology Drugs Q3 Performance: What to Expect (Zacks)
09:29AM	Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings (Zacks)
Oct-23-25 11:55AM	eschbach's Shiftconnector Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience (PR Newswire)
10:00AM	Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
06:45AM	Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025 (Business Wire)
06:00AM	FDA Grants Priority Review for KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer (Business Wire)
Oct-21-25 01:41PM	SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments (Zacks)
12:21PM	Merck Kicks Off $3 Billion Expansion in Virginia (GuruFocus.com)
11:50AM	Analyst Says He's Buying Merck (MRK) as 'Market Turns Towards Quality' (Insider Monkey)
08:58AM	Will BMY's Growth Portfolio Drive Third-Quarter Results? (Zacks)
08:29AM	MSD initiates construction on $3bn Virginia drug manufacturing site (Pharmaceutical Technology)
06:55AM	Iambic partners with Jazz; Merck breaks ground on $3B plant (BioPharma Dive)
Oct-20-25 05:50PM	Merck (MRK) Outpaces Stock Market Gains: What You Should Know (Zacks)
05:12PM	JPMorgan Says Correction Will Be Healthy 5 Safe High-Yield Dividend Stocks (24/7 Wall St.)
10:10AM	Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings (Zacks)
09:07AM	2 Beaten-Down Stocks to Buy and Hold for the Next Decade (Motley Fool)
08:45AM	KEYTRUDA (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
06:48AM	Merck breaks ground on $3B manufacturing plant in Virginia (Fox Business)
06:45AM	Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia (Business Wire)
Oct-19-25 08:45AM	Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial (Business Wire)
Oct-18-25 10:35AM	KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer (Business Wire)
10:30AM	Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients (Investor's Business Daily)
10:30AM	KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery (Business Wire)
06:00AM	KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen (Business Wire)
Oct-17-25 12:20PM	Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings? (Zacks)
11:09AM	Bank of America Securities Reduces PT on Merck & Co., Inc. (MRK), Keeps a Buy Rating (Insider Monkey)
03:24AM	Trump Strikes Deal With Merck KGaA on Tariffs, IVF Costs (Bloomberg)
Oct-16-25 09:00AM	Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now? (Zacks)
06:45AM	Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer (Business Wire)
02:06AM	Citi Raises Price Target on Merck (MRK), Citing Strong Pipeline and Oncology Strength (Insider Monkey)
02:00AM	Germanys Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets (The Wall Street Journal)
Oct-14-25 05:50PM	Merck (MRK) Declines More Than Market: Some Information for Investors (Zacks)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DAVID WILLIAMS	Officer	Nov 03 '25	Proposed Sale	83.59	8,614	720,040		Nov 03 04:09 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Aug 04 '25	Option Exercise	79.29	17,119	1,357,366	41,445	Aug 05 08:46 AM
Guindo Chirfi	Chief Marketing Officer	Aug 04 '25	Option Exercise	79.29	36,903	2,926,039	107,409	Aug 05 08:43 AM
Smart Dalton E. III	SVP Fin. - Global Controller	May 03 '25	Option Exercise	83.18	2,050	170,519	10,127	May 05 04:23 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '25	Option Exercise	84.71	464	39,305	8,242	May 02 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	May 02 '25	Option Exercise	83.26	381	31,722	8,464	May 02 04:18 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '25	Option Exercise	83.26	2,262	188,334	24,061	May 02 04:14 PM
Romanelli Joseph	President, Human Health Int?l	Apr 30 '25	Option Exercise	84.71	2,063	174,757	22,816	May 02 04:14 PM
Larson Betty D	EVP, Chief HR Officer	Apr 30 '25	Option Exercise	84.71	11,350	961,458	11,350	May 02 04:12 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Option Exercise	58.08	5,000	290,400	12,040	Apr 29 04:04 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Sale	82.76	4,262	352,723	7,778	Apr 29 04:04 PM
DALTON SMART	Officer	Apr 25 '25	Proposed Sale	82.76	4,262	352,723		Apr 25 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 19 '25	Sale	84.09	8,500	714,745	30,705	Feb 20 04:01 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 19 '25	Proposed Sale	84.09	8,500	714,745		Feb 19 05:09 PM
DAVID WILLIAMS	Officer	Feb 13 '25	Proposed Sale	85.34	6,000	512,057		Feb 13 04:10 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 13 '25	Sale	85.34	6,000	512,057	24,123	Feb 13 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 08 '25	Option Exercise	87.28	13,002	1,134,815	45,609	Feb 11 02:59 PM
THULIN INGE G	Director	Feb 06 '25	Buy	88.25	2,833	250,000	2,933	Feb 07 04:09 PM
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Feb 06 '25	Sale	88.76	2,361	209,551	7,085	Feb 07 04:07 PM
BAKER DOUGLAS M JR	Director	Feb 05 '25	Buy	88.50	15,000	1,327,500	16,000	Feb 07 04:04 PM
CRISTAL DOWNING	Officer	Feb 06 '25	Proposed Sale	88.76	2,361	209,551		Feb 06 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience